Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dedicator of cytokinesis protein 2 (DOCK2)
- Target
- DOCK2
- Molecular classification
- Guanine nucleotide exchange factor (GEF), Cytoskeletal regulator, Signaling protein
01
Overview
Dedicator of cytokinesis protein 2 (DOCK2) is a large cytosolic protein and a member of the DOCK family of guanine nucleotide exchange factors (GEFs), specifically in the DOCK-A subfamily. DOCK2 is predominantly expressed in immune and hematopoietic cells, where it plays a central role in activating the small GTPase Rac, regulating actin cytoskeleton dynamics necessary for cell migration, adhesion, proliferation, and immune synapse formation. It orchestrates homeostasis and functional responses of various immune cells, including T and B lymphocytes, neutrophils, and dendritic cells, influencing chemotaxis and immune activation. Beyond immunity, DOCK2 regulates platelet development and function and has been implicated in disorders of hemostasis, inflammation, immunodeficiency, viral pathogenesis (including COVID-19 severity), cancer progression (via mutation or altered expression), and neuroinflammation. Pharmacological inhibition or genetic loss of DOCK2 impairs immune responses and platelet function, establishing it as both a research and emerging therapeutic target in autoimmunity, thrombosis, and inflammatory diseases.
- Other names
- Dedicator of cytokinesis 2KIAA0209IMD40
02
Mechanism of action
Inhibitors target the GEF activity for Rac GTPases, suppressing actin cytoskeletal rearrangement and immune cell/platelet activation
03
Biological functions
Regulation of cytoskeletal actin dynamicsSignal transduction (via Rac GTPases)Immune cell migration, activation, and homeostasisPlatelet biogenesis and functionLymphocyte chemotaxis and activationNeutrophil and dendritic cell migration
04
Disease associations
Immunodeficiency/hematopoietic disorders (including IMD40, a combined immunodeficiency)Inflammation (acute and chronic)Infection (e.g., susceptibility to viral/bacterial infections, COVID-19 severity)Autoimmune diseaseCancer (mutational role in solid tumors like esophageal and colorectal adenocarcinoma)Thrombotic/bleeding disordersNeurodegenerative disease (implicated in Alzheimer’s disease)
05
Safety considerations
Increased susceptibility to infections (due to impaired leukocyte migration and activation)Bleeding risk (from effects on platelet function and production)Potential impact on immunity (impaired T and B cell responses, reduced NK cell cytotoxicity)
06
Interacting drugs
CPYPP (small-molecule DOCK2 inhibitor)
07
Biomarkers
Null (No validated, specific biomarkers widely used for patient selection or monitoring DOCK2-targeted therapy)
Beyond the preview
Go deeper on Dedicator of cytokinesis protein 2 (DOCK2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Dedicator of cytokinesis protein 2 (DOCK2).